Back to Results
First PageMeta Content
Merck / Amines / Alcohols / Ketones / Pharmaceutical Benefits Scheme / Simvastatin / Statin / Ezetimibe / Methadone / Chemistry / Organic chemistry / Phenols


Microsoft Word - PBAC agenda for web publication July 2012 revised include pitavastatin.doc
Add to Reading List

Document Date: 2015-01-04 21:20:13

Open Document

File Size: 59,92 KB

Share Result on Facebook

Company

Sanofi Aventis Australia Pty Ltd / Janssen-Cilag Pty Ltd / Norgine Pty Ltd / Amgen Australia Pty Ltd / Roche Products Pty Limited / Dohme (Australia) Pty Limited / Public Merck Sharp & Dohme Australia Pty Ltd / Pfizer Australia Pty Ltd / Novartis Pharmaceuticals Australia Pty Ltd / Gilead Sciences Pty Ltd / Allergan Pty Ltd / Servier Laboratories (Australia) Pty Ltd / Bristol-Myers Squibb Australia Pty Ltd / Pradax (Minor submission) Boehringer Ingelheim Pty Ltd / GlytactinTM Cambrooke Australia Pty Ltd / Aspen Pharma Pty Ltd / AFT Pharmaceuticals Pty Limited / Merck Serono Australia Pty Ltd / Public Hospital Authority Required Novartis Pharmaceuticals Australia Pty Ltd / Forte AFT Pharmaceuticals Pty Limited / Alexion Pharmaceuticals Australasia Pty Ltd / CSL Limited / Abbott Australasia Pty Ltd / Boehringer Ingelheim Pty Ltd / Alexion Pharmaceuticals Pty Ltd / /

Country

Australia / /

Event

FDA Phase / /

Facility

Public Janssen-Cilag Pty Ltd Hospital / Hospital Authority Required / BOTULINUM TOXIN TYPE A PURIFIED NEUROTOXIN COMPLEX / /

IndustryTerm

prevention of stroke / food / heart failure therapy / treatment of symptomatic systolic heart failure / listed products / treatment of HER2 positive locally advanced breast cancer / /

MedicalCondition

brain disorder / headaches / multiple myeloma / Lymphoma / Hyperphenylalaninaemia Re-submission / systemic embolism / urinary incontinence / metastatic advanced prostate cancer / carcinoma / hepatitis C / severe dry eye syndrome / chronic liver failure / optimal heart failure / symptomatic systolic heart failure / phenylketonuria / cystic fibrosis / resistant prostate cancer / prostate cancer / liver disease / hormone-resistant prostate cancer / breast cancer / V lupus nephritis / chronic functional constipation / hypertension / cancer / disease / NSCLC / P. aeruginosa infection / progressive disease / IV melanoma / stroke / tumour / diabetes / Hepatic encephalopathy / primary and secondary osteoporosis / Bone metastases / Attention deficit hyperactivity disorder / patients genetic disorder / non-valvular atrial fibrillation / nonsmall cell lung cancer / chronic migraine / open-angle glaucoma / hyperphenylalaninaemia / atrial fibrillation / infection / ocular hypertension / TIMOLOL Glaucoma / chronic severe disabling pain / chronic hepatitis C / /

MedicalTreatment

Chemotherapy / oral therapy / /

NaturalFeature

Schedule fall / /

Organization

PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE / World Health Organization / Public Hospital / Medicare / Private Hospital / Working Party / Public Janssen-Cilag Pty Ltd Hospital / /

Position

General / Chairman / nurse / /

Product

Herceptin / Emend / olmesartan medoxomil / Concerta / June 2012 TELAPREVIR / Restricted Benefit / SIMVASTATIN / June 2012 MYCOPHENOLATE SODIUM / Soliris / Zometa / peginterferon / Phenobarbitone Injection / Vytorin / prednisolone / Kuvan / Myfortic / ribavirin / Cosopt / Xifaxan / prednisone / Vitamin A / June 2012 SAPROPTERIN / lactulose / METHYLPHENIDATE HYDROCHLORIDE / atenolol / Sutent / Tarceva / Phenobarbitone Injection® (Minor submission) / Hylo® / VitA-POS® (Minor submission) / EZETIMIBE / ZOLEDRONIC ACID / Tarceva® (Major submission) / Stelara® (Minor submission) / Emend® (Minor submission) / Xgeva® (Minor submission) / /

Technology

transplantation / Chemotherapy / genotype / /

SocialTag